179950-69-7 Usage
Uses
Used in Pharmaceutical Industry:
Methyl 2-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-7-carboxylate is used as a key intermediate in the synthesis of pharmaceutical compounds for its potential therapeutic properties. Its unique structure allows for the development of new drugs with specific targets and mechanisms of action.
Used in Agrochemical Industry:
In the agrochemical sector, methyl 2-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-7-carboxylate is utilized as a precursor in the production of agrochemicals, such as pesticides and herbicides. Its reactivity enables the creation of molecules with targeted effects on pests and weeds, improving crop protection and yield.
Used in Materials Science:
Methyl 2-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-7-carboxylate is employed as a building block in the development of advanced materials with specific properties. Its incorporation into polymers and other materials can enhance their performance, durability, and functionality in various applications, such as coatings, adhesives, and composites.
It is crucial to handle methyl 2-methyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazine-7-carboxylate with care and follow safety guidelines to minimize potential harmful effects due to its chemical nature.
Check Digit Verification of cas no
The CAS Registry Mumber 179950-69-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,7,9,9,5 and 0 respectively; the second part has 2 digits, 6 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 179950-69:
(8*1)+(7*7)+(6*9)+(5*9)+(4*5)+(3*0)+(2*6)+(1*9)=197
197 % 10 = 7
So 179950-69-7 is a valid CAS Registry Number.
179950-69-7Relevant academic research and scientific papers
1, 4-benzoxazine derivative and pharmaceutical compositions containing the same
-
, (2008/06/13)
A 1,4-benzoxazine derivative of the following formula (I): STR1 or a pharmaceutically acceptable salt thereof is disclosed. The compound of the present invention is useful as a medicament for preventing or treating disorders induced by intracellular acidosis during myocardial ischemia, such as cardiac dysfunction, myocardial necrosis, arrhythmia, reperfusion injury, and the like, which are observed in ischemic heart diseases (e.g. myocardial infarction, angina pectoris, etc.).
Design, synthesis and quantitative structure-activity relationship study of N-(3-oxo-3,4-dihydro-2H-benzo[1,4]oxazine-7-carbonyl)guanidine derivatives as potent Na/H exchange inhibitors
Yamamoto, Takeshi,Hori, Manabu,Watanabe, Ikuo,Tsutsui, Hisayoshi,Harada, Kengo,Ikeda, Shoji,Maruo, Joji,Morita, Tominori,Ohtaka, Hiroshi
, p. 1975 - 1983 (2007/10/03)
Inhibition of the Na/H exchanger is a promising approach for treating ischemia-reperfusion injury, but no clinical agent is yet available. Recently, we established the structural requirements for potent inhibitors of the Na/H exchanger. In the present wor
